KR870002269A - 새로운 bbm-1675c 및 d 항종양성 항생물질 및 그 제조방법 - Google Patents

새로운 bbm-1675c 및 d 항종양성 항생물질 및 그 제조방법 Download PDF

Info

Publication number
KR870002269A
KR870002269A KR1019860007092A KR860007092A KR870002269A KR 870002269 A KR870002269 A KR 870002269A KR 1019860007092 A KR1019860007092 A KR 1019860007092A KR 860007092 A KR860007092 A KR 860007092A KR 870002269 A KR870002269 A KR 870002269A
Authority
KR
South Korea
Prior art keywords
bbm
hydrolyzed
recovered
inorganic
organic acids
Prior art date
Application number
KR1019860007092A
Other languages
English (en)
Other versions
KR920010226B1 (ko
Inventor
골리크 저지
Original Assignee
아이삭 자아코브스키
브리스톨-마이어즈 컴페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이삭 자아코브스키, 브리스톨-마이어즈 컴페니 filed Critical 아이삭 자아코브스키
Publication of KR870002269A publication Critical patent/KR870002269A/ko
Application granted granted Critical
Publication of KR920010226B1 publication Critical patent/KR920010226B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/03—Actinomadura

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

내용 없음

Description

새로운 BBM1675C 및 D 항종향성 항생물질 및 그 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. (a)무정형 고체이고,
    (b)메탄올, 에탄올, 에틸아세테이트, 아세톤, 테트라히드로푸란 및 클로로포름에 용해하며,
    (c)실리카겔 박층 크로마토그래피에서 톨루엔 : 아세톤(3 : 2, v/v) 용매계로써 Rf값 0.28를 나타내고,
    (d)고분해성 FAB질량 분광기에 의해서 측정한 추정 분자량이 855이며,
    (e)제1도에 나타낸 것과 같이 메탄올 용액중에 산 또는 염기의 첨가에 의해서 뚜렷한 변화가 생기지 않고 210nm(a=21,770), 274nm(a=9,340) 및 313nm(쇼울더) (a=4,190)에서 자외선 흡수 최대치 및 흡수성을 나타내는 자외선 흡수 스펙트럼을 갖고,
    (f)제3도에 나타낸 것과 같이 다음의 점에서 주 흡수정점을 나타내는 적외선 흡수 스펙트럼(KBr,박막)을 갖고,
    540,740,955,990,1017,1065,1080,1118,1150,1250,1305,1325,1340,1370,1385,1440,1690,1705,1735,2900,2920,2930,2970, 및 3450cm-1
    (g)제5도에 나타낸 것과 분자이온 [M+H]+이 856을 나타내는 저분해성 질량 스펙트럼을 가지며,
    (h)제7도에 나타낸 것과 같이 CDCl3중에서 테트라메틸 실란으로 부터 다음의 점에서 신호를 나타내는 360MHz 양자 공명 스펙트럼을 갖고,
    6.54(1H,dd, J=7.7, 7.0); 6.21(1H , brs); 5.87(1H, d J=9.6);5.78(1H, dd, J=9.6, 1.5);5.66 (1H, brd, J=2.9); 4.94 (1H, dd, J=10.3, 1.8); 4.61 (1H, d, J=7.7); 4.25 (1H, s); 4.09 (1H, q, J=2.6); 3.97 (1H, t, J=9.6); 3.92-3.53 (10H), 3.45 (1H, dt, J=10.3, 4.0); 3.37 (3H, s); 2.77 (1H, m); 2.69 (1H, dt, J=9.9, 5.2); 2.49 (1H, dd, J=10.3M 2.6); 2.48 (3H, s); 2.30 (2H, m); 2.13 (1H, m); 2.09 (3H, s); 1.50 (2H, m); 1.37 (3H, d, J=5.9); 1.32 (3H, d, J=6.3); 및 1.08 (6H) ppm.
    (ⅰ)제9도에 나타낸 것과 같이 CDCl3중에서 테트라메틸 실란으로부터 다음의 점에서 신호를 나타내는 90.6MHz 탄소-13자기 공평 스펙트럼을 갖는 것이 특징인 순수한 형태의 항종양성 항생물질.
    13.7, 17.5, 19.8, 22.3, 22.7, 23.5, 34.2, 35.2, 39.5, 47.7, 52.7, 55.8, 56.1, 57.7, 62.4, 64.7, 67.4, 69.3, 69.8, 71.9, 76.1, 77.1,77.7, 79.7, 83.2, 88.4, 97.3, 99.7, 123.4, 124.6, 130.1, 및 193.1ppm.
  2. (a)무정형 고체이고,
    (b)메탄올, 에탄올, 아세톤 및 테트라하드로푸란에 용해하고 클로로포름에 약간 용해하며,
    (c)실리카겔 박층크로마토그래피에서 클로로포름: 에탄올(5:0.5,V/V) 용매계로써 Rf값 0.22을 나타내고, 역상 실리카겔 박층크로마토그래피에서 메탄올:물 (70:30, V/V) 용매계로써 Rf값 0.37을 나타내며
    (d)고분해성 FAB질량 분광기에 의해서 측정한 추정 분자량이 695이고,
    (e)제2에 나타낸 것과 같이 메탄올 용액중에 산 또는 염기의 첨가에 의해서 뚜렷한 변화가 생기지 않고 214nm(a=27,000), 274nm(a=12,800)및 (a=5,400)에서 자외선 흡수 최대치 및 흡수성을 나타내는 자외선 흡수 스펙트럼을 갖으며,
    (f)제4도에 나타낸 것과 같이 다음의 점에서 주 흡수정점을 나타내는 적외선 흡수 스펙트럼(KBr,박막)을 갖고,
    735, 755, 910, 960, 1000, 1020, 1085, 1150, 1195, 1250, 1310, 1335, 1365, 1385, 1445, 1510, 1685, 1720, 1735, 2880, 2930, 2960, 3400cm-1.
    (g)제3도에 나타낸 것과 분자이온 [M+H]+이 696을 나타내는 저분해성 질량 스펙트럼을 가지며,
    (h)제8도에 나타낸 것과 같이 CDCl3+10% CD3OD중에서 테트라메틸실란으로 부터 다음의 점에서 신호를 나타내는 360MHz 양자 공명 스펙트럼을 갖고,
    6.43(1H, dd, J=4.4,10.3) ; 6.13 (1H, s) ; 5.81(1H, d, J=8.8) ; 5.70(1H, d J=8.8) ; 5.48 (1H, 6brs) ; 4.48 (1H, d, J=8.1) ; 4.02 (1H, d,J=2.0) ; 3.95-3.80 (solvent background) ; 3.77 (1H, t, J=9.0) ; 3.70-3.40(11H, brm) ; 3.35 (1H, m) ; 3.28(3H, s) ; 3.22 (3H, brs) ; 2.66-2.55(2H, m) ; 2.38 (3H, s) ; 2.23-2.12 (2H, m) ; 1.42 (1H, brdt) ; 1.22 (3H, d, J=5.9) ; 0.94 (3H, d, J=6.6) ; 및 0.87 (3H, d, J-5.9)ppm.
    (ⅰ)제10도에 나타낸 것과 같이 CDCl3+10% CD3OD중에서 테트라메틸 실란으로 부터 다음의 점에서 신호를 나타내는 90.6MHz 탄소-13 자기 공명 스펙트럼을 갖는 것이 특징인 순수한 형태의 항종양성 항생물질 BBM-1675D.
    17.5, 21.6, 22.2, 23.0, 33.4, 39.2, 46.4, 52.3, 55.8, 62.1, 67.8, 69.8, 70.1, 71.3, 75.9, 77.1, 78.1, 82.4, 83.3, 88.2, 97.4, 99.6, 122.6, 124.8, 130.1, 130.8, 134.3, 148.7 및 192.8ppm.
  3. 상당량의 BBM-1675C가 생성될 때까지 BBM-1675A1또는 BBM-1675A2를 무기 또는 유기산으로 가수분해 시키고, 그 반응매질로부터 BBM-1675C를 회수하는 것을 특징으로 하는 항종양성 항생물질 BBM-1675C의 제조방법.
  4. 상당량의 BBM-1675D가 생성될때까지 BBM-1675A1또는 BBM-1675A2를 무기 또는 유기산으로 가수분해 시키고, 그 반응매질로부터 BBM-1675D를 회수하는 것을 특징으로 하는 항종양성 항생물질 BBM-1675D의 제조방법.
  5. 상당량의 BBM-1675D가 생성될때까지 BBM-1675C를 무기 또는 유기산으로 가수분해 시키고, 그 반응매질로부터 BBM-1675D를 회수하는 것을 특징으로 하는 항종양성 항생물질 BBM-1675D의 제조방법.
  6. 상당량의 BBM-1675C가 생성될때까지 BBM-1675A1또는 BBM-1675A2의 혼합물을 무기 또는 유기산으로 가수분해 시키고, 그 반응매질로부터 BBM-1675C를 회수하는 것을 특징으로 하는 항종양성 항생물질 BBM-1675C의 제조방법.
  7. 상당량의 BBM-1675D가 생성될때까지 BBM-1675A1또는 BBM-1675A2를 무기 또는 유기산으로 가수분해 시키고, 그 반응매질로부터 BBM-1675D를 회수하는 것을 특징으로 하는 항종양성 항생물질 BBM-1675D의 제조방법.
  8. BBM-1675C 또는 BBM-1675D의 효과적인 항균 억제량과 제약학적 담체 또는 희석제를 혼합하여된 제약학적 조성물.
  9. BBM-1675C 또는 BBM-1675D의 효과적인 종양 억제량과 제약학적 담체 또는 희석제를 혼합하여된 제약학적 조성물.
  10. BBM-1675C 또는 BBM-1675D의 효과적인 항균 투여량을 동물 숙주에 투여함을 특징으로 하는 세균성 질병에 걸린 동물 숙주를 임상치료하는 방법.
  11. BBM-1675C 또는 BBM-1675D의 종양억제량을 동물 숙주에 투여함을 특징으로 하는 BBM-1675C 또는 BBM-1675D에 예민한 악성 종양에 감염된 동물숙주를 임상치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860007092A 1985-08-27 1986-08-26 새로운 bbm-1675c 및 d 항종양성 항생물질 및 그 제조방법 KR920010226B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77033585A 1985-08-27 1985-08-27
US770335 1985-08-27

Publications (2)

Publication Number Publication Date
KR870002269A true KR870002269A (ko) 1987-03-30
KR920010226B1 KR920010226B1 (ko) 1992-11-21

Family

ID=25088206

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860007092A KR920010226B1 (ko) 1985-08-27 1986-08-26 새로운 bbm-1675c 및 d 항종양성 항생물질 및 그 제조방법

Country Status (26)

Country Link
JP (2) JPH0733393B2 (ko)
KR (1) KR920010226B1 (ko)
AT (1) AT392971B (ko)
AU (1) AU604464B2 (ko)
BE (1) BE905332A (ko)
CA (1) CA1307256C (ko)
CH (1) CH668598A5 (ko)
CY (1) CY1676A (ko)
DE (1) DE3629052C2 (ko)
DK (1) DK170671B1 (ko)
ES (1) ES2002728A6 (ko)
FI (1) FI83422C (ko)
FR (1) FR2586686B1 (ko)
GB (1) GB2179649A (ko)
GR (1) GR862160B (ko)
HK (1) HK793A (ko)
HU (1) HU197915B (ko)
IE (1) IE59204B1 (ko)
IL (1) IL79519A0 (ko)
IT (1) IT1229176B (ko)
LU (1) LU86562A1 (ko)
NL (1) NL8602165A (ko)
PT (1) PT83261B (ko)
SE (2) SE469632B (ko)
SG (1) SG109692G (ko)
ZA (1) ZA865796B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1215212A3 (en) * 1987-01-30 2003-05-21 Wyeth Holdings Corporation Dihydro derivatives of LL-E33288 antibiotics
US4916065A (en) * 1988-06-10 1990-04-10 Bristol-Myers Company BU-3420T Antitumor antibiotic
US5028536A (en) * 1989-03-15 1991-07-02 Bristol-Myers Squibb Company Antitumor antibiotic BMY-41339
US5086045A (en) * 1989-03-15 1992-02-04 Bristol-Myers Squibb Company Antitumor antibiotic
CA2027601A1 (en) * 1989-11-06 1991-05-07 Koko Sugawara Antitumor antibiotic bu-3983t
CA2039789A1 (en) * 1990-04-27 1991-10-28 Samuel J. Danishefsky Calicheamicinone, derivatives and analogs thereof and methods of making the same
US5116845A (en) * 1990-05-04 1992-05-26 Bristol-Myers Company BU-3420T antitumor antibiotic
US5264586A (en) * 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3148023A1 (de) * 1981-12-04 1983-06-09 Rudolf Dipl.-Ing. 8901 Oberottmarshausen Fischer Heizungskessel fuer heisse rauchgase
US4578271A (en) * 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
NZ208013A (en) * 1983-05-16 1987-07-31 Bristol Myers Co Antitumour antibiotic bbm-1675 and production by cultivating actinomadura verrucosospora
JPS606194A (ja) * 1983-06-23 1985-01-12 Meiji Seika Kaisha Ltd 新規抗生物質ｓｆ−２２８８及びその製造法
US4530835A (en) * 1983-07-08 1985-07-23 Warner-Lambert Company CL-1577 Antibiotic compounds and their production

Also Published As

Publication number Publication date
GR862160B (en) 1986-12-31
DK170671B1 (da) 1995-11-27
LU86562A1 (fr) 1987-03-06
NL8602165A (nl) 1987-03-16
IE59204B1 (en) 1994-01-26
FI863405A (fi) 1987-02-28
FR2586686A1 (fr) 1987-03-06
SE469632B (sv) 1993-08-09
SG109692G (en) 1992-12-24
IT1229176B (it) 1991-07-23
BE905332A (fr) 1987-02-26
ES2002728A6 (es) 1988-10-01
PT83261A (en) 1986-09-01
CA1307256C (en) 1992-09-08
FR2586686B1 (fr) 1990-02-02
IT8621527A0 (it) 1986-08-26
AU6175186A (en) 1987-03-05
FI83422C (fi) 1991-07-10
SE9200428D0 (sv) 1992-02-13
JPS62116589A (ja) 1987-05-28
HK793A (en) 1993-01-15
HUT44035A (en) 1988-01-28
HU197915B (en) 1989-06-28
FI83422B (fi) 1991-03-28
JPH0733393B2 (ja) 1995-04-12
AU604464B2 (en) 1990-12-20
PT83261B (pt) 1989-05-12
FI863405A0 (fi) 1986-08-22
DK406086D0 (da) 1986-08-26
CY1676A (en) 1993-10-10
SE8603597L (sv) 1987-02-28
GB8620118D0 (en) 1986-10-01
IL79519A0 (en) 1986-10-31
DE3629052C2 (de) 1995-09-28
AT392971B (de) 1991-07-25
GB2179649B (ko) 1989-10-25
SE9200428L (sv) 1993-08-14
DK406086A (da) 1987-02-28
ATA231786A (de) 1990-12-15
GB2179649A (en) 1987-03-11
KR920010226B1 (ko) 1992-11-21
CH668598A5 (de) 1989-01-13
JPH07233186A (ja) 1995-09-05
ZA865796B (en) 1987-04-29
IE862280L (en) 1987-02-27
DE3629052A1 (de) 1987-05-07
SE8603597D0 (sv) 1986-08-26

Similar Documents

Publication Publication Date Title
CA2336809A1 (en) Water miscible macrolide solutions
FI934000A (fi) Nya estrar av bi- och tricykliska aminoalkoholer, deras framstaellning och deras anvaendning i laekemedel
KR870002269A (ko) 새로운 bbm-1675c 및 d 항종양성 항생물질 및 그 제조방법
GB1162248A (en) Epipodophyllotoxin Derivatives
KOBAYASHI et al. Alkaloidal constituents of Leucojum asetivum L.(Amaryllidaceae)
PT925065E (pt) Composicoes de eritromicina misturaveis em agua
HUP9802573A2 (hu) Csontképződést elősegítő benzotián- vagy benzotiepánszármazékot és biolebontható polimert tartalmazó gyógyászati készítmény
ATE16278T1 (de) Hydroxybenzylamino-aryl verbindungen, verfahren zur deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
JPS5746988A (en) Novel penicillin derivative and its preparation
SE8305538L (sv) Polysilylerat kanamycin a eller b som mellanprodukt vid framstellning av derivat av kanamycin a och b
EP0184921A3 (en) Erythromycin derivatives
JPS56103185A (en) Malonamidoxa-dethia-cephem compound
JPS56122397A (en) Marcolides
JPS5711986A (en) Okadaic acid, its salt, and its ester
GB1163106A (en) 4'-Demethyl-Epipodophyllotoxin Derivatives
GB1101361A (en) The new antibiotic, shinomycin, and production thereof
GB1504994A (en) Naphthyridinomycin antibiotics and preparation thereof
SE329371B (ko)
JPS5448782A (en) Deesterification of cephem compound ester
GB1493186A (en) Antibiotic bn-130 substance and the production thereof
JPS56154433A (en) Quinone compound and its preparation
JPS5620597A (en) Novel physiologically active substance
Horii et al. Synthesis of Bisanhydroaklavinone
GB1368478A (en) Antibiotic
JPS5572192A (en) 1-carba-2-penem-3-carboxylic acid derivative and its preparation

Legal Events

Date Code Title Description
A201 Request for examination
E601 Decision to refuse application
E902 Notification of reason for refusal
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19950826

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee